##  [Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®\* in chronic myeloid leukemia trial](/us-en/news/media-releases/novartis-investigational-stamp-inhibitor-asciminib-abl001-shows-superior-mmr-rate-bosulif-chronic-myeloid-leukemia-trial-0 "Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial") 

  Dec 08, 2020